Literature DB >> 17196666

CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Chad Laurie1, Ashley Reynolds, Ozlem Coskun, Erik Bowman, Howard E Gendelman, R Lee Mosley.   

Abstract

Adoptive transfer of lymphoid cells from Copolymer 1 (Cop-1) immunized mice leads to T cell accumulation within the substantia nigra, modulation of microglial responses, upregulation of glial cell derived neurotrophic factor, and protection of the nigrostriatum following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication. We now demonstrate that T cells isolated from lymph nodes and spleens of Cop-1 immunized animals protect the nigrostriatal system from MPTP-induced neurodegeneration in a dose-dependent manner. CD4+ T cells elicited the most significant neuroprotective response while high titers of anti-Cop-1 antibodies showed no effect. These data further support the use of immunomodulatory strategies for Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17196666     DOI: 10.1016/j.jneuroim.2006.11.009

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  43 in total

Review 1.  Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases.

Authors:  Lisa M Kosloski; Duy M Ha; Jessica A L Hutter; David K Stone; Michael R Pichler; Ashley D Reynolds; Howard E Gendelman; R Lee Mosley
Journal:  J Neurochem       Date:  2010-05-26       Impact factor: 5.372

2.  Expression of dopaminergic receptors on human CD4+ T lymphocytes: flow cytometric analysis of naive and memory subsets and relevance for the neuroimmunology of neurodegenerative disease.

Authors:  Natasa Kustrimovic; Emanuela Rasini; Massimiliano Legnaro; Franca Marino; Marco Cosentino
Journal:  J Neuroimmune Pharmacol       Date:  2014-03-29       Impact factor: 4.147

Review 3.  Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors:  Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal:  Exp Neurol       Date:  2007-07-17       Impact factor: 5.330

4.  Low-Dose Maraviroc, an Antiretroviral Drug, Attenuates the Infiltration of T Cells into the Central Nervous System and Protects the Nigrostriatum in Hemiparkinsonian Monkeys.

Authors:  Susanta Mondal; Suresh B Rangasamy; Avik Roy; Sridevi Dasarathy; Jeffrey H Kordower; Kalipada Pahan
Journal:  J Immunol       Date:  2019-05-01       Impact factor: 5.422

5.  Induction of Adaptive Immunity Leads to Nigrostriatal Disease Progression in MPTP Mouse Model of Parkinson's Disease.

Authors:  Goutam Chandra; Avik Roy; Suresh B Rangasamy; Kalipada Pahan
Journal:  J Immunol       Date:  2017-04-26       Impact factor: 5.422

6.  Vaccine for the mind: Immunity against self at the choroid plexus for erasing biochemical consequences of stressful episodes.

Authors:  Michal Schwartz; Kuti Baruch
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 7.  Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?

Authors:  Marina Romero-Ramos; Marianne von Euler Chelpin; Vanesa Sanchez-Guajardo
Journal:  Hum Vaccin Immunother       Date:  2014-03-26       Impact factor: 3.452

Review 8.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

9.  GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice.

Authors:  Lisa M Kosloski; Elizabeth A Kosmacek; Katherine E Olson; R Lee Mosley; Howard E Gendelman
Journal:  J Neuroimmunol       Date:  2013-10-29       Impact factor: 3.478

10.  Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets.

Authors:  Ashley D Reynolds; David K Stone; R Lee Mosley; Howard E Gendelman
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.